Recon: Australia provisionally authorizes AstraZeneca vaccine; BMS, Sanofi ordered to pay Hawaii $834M over Plavix warning label

• Moderna expects to supply second 100 million vaccine doses to US by May-end (Reuters)
• Low vaccine supply pushes US vaccination timeline to at least late May: Fauci (Reuters)
• Bristol-Myers, Sanofi ordered to pay Hawaii $834M over Plavix warning label (Reuters) (STAT)
• Bluebird suspends studies of sickle cell gene therapy following cancer diagnoses in two more treated patients (STAT)
• Once again, senators want GAO to probe the role of PBMs in prescription drug pricing (STAT)
• Novavax to complete US vaccine trial enrolment in record time (FT)
• How scientists saved Trump's FDA from politics (The Hill)

• EU adds anti-variant clauses to new COVID vaccine supply deals (Reuters)
• EU seeks new COVID-19 vaccine deal with Moderna, AZ flags doses made outside EU (Reuters)
• Australia approves AstraZeneca vaccine, bolstering inoculation programme (Reuters)
• Japan to start inoculation drive Wednesday amid shortage of special syringes (Reuters 1, 2)
• UK auditing Indian vaccine site amid scramble for shots – sources (Reuters)
• Hong Kong advisory panel approves China's Sinovac COVID-19 vaccine for emergency use (Reuters)
• North Korean hackers tried to steal Pfizer vaccine know-how, lawmaker says (Reuters)
• Ebola vaccination campaign begins in Democratic Republic of Congo (Reuters) (BBC)
• WHO alerts six African countries after Ebola outbreaks (Reuters)
• Five dead in new Ebola outbreak in Guinea (Reuters)

• Why the three biggest vaccine makers failed on Covid-19 (FT)
• Covid-Linked Syndrome in Children Is Growing and Cases Are More Severe (NYTimes)
• Scientists Are Trying to Spot New Viruses Before They Cause Pandemics (NYTimes)
• Potential for New Coronaviruses May Be Greater Than Known (NYTimes)
• My Teens are Coronavirus Vaccine Guinea Pigs (NYTimes)
• Another new coronavirus variant seen in the UK (BBC)
• New Coronavirus Variants Appear To Have Evolved In The US (NPR)
• China arrests leader of fake vaccine scam (BBC)
• First 550,000 doses of Chinese Sinopharm's vaccine arrive in Hungary (Reuters)
• The search for new Covid drugs — and a researcher’s reason for optimism (STAT)
• Palestinians accuse Israel of preventing COVID-19 vaccine transfer to Gaza (Reuters)
• South Africa wants to return 1 million AstraZeneca vaccine doses to Serum Institute: report (Reuters)
• South Africa plans to share AstraZeneca vaccine, first J&J shots expected (Reuters)
• South Africa medical association says J&J vaccines could arrive on Tuesday (Reuters)
• Eyeing variants, Adagio starts phase 1 trial of COVID-19 antibody (Fierce)
• Germany plans to offer free rapid coronavirus tests from March 1 (Reuters)
• US FDA ‘Project Post COVIDity’ Will Track Infection Impact On Cancer Patients Using Real-World Data (Pink Sheet)

• Trump’s vaccine tsar launches European biotech roll-up (FT) (STAT) (BioPharmaDive)
• Pfizer, Verily-backed Alzheimer's biotech Cortexyme hit by FDA partial hold over liver toxicity (Fierce)
• AstraZeneca hands chief £15.4m pay package (FT) (Endpoints)
• EU Fast-Track Fail For Another BMS CAR-T Cell Therapy (Pink Sheet)
• Khosla bets big on SPAC boom, raising $1.2 billion for 3 vaguely targeted blank-check companies (Endpoints)
• Cortexyme's unorthodox Alzheimer's approach tripped up by FDA hold (Endpoints)
• Celltrion's inflammatory disease drug Yuflyma gets EU approval for 13 indications (Pharmafile)
• Pazdur Unplugged: US FDA’s “Project Livin’ Label” Shows Back Story On Cancer Drug Approvals (Pink Sheet)
• Industry Urged To Use ICH Q12 Protocols To Ease Post-Approval Changes For Analytical Methods (Pink Sheet)
• MHRA launches public consultation on reclassification of two contraceptive pills (PharmaTimes)
• Japan’s 1st Humira Biosimilar Hits Market (PharmaJapan)
• Daiichi Sankyo and AstraZeneca's breast cancer drug Enhertu approved in UK (Pharmafile)
• 'I’m not trying to rebuild an ego': Neil Woodford appeals to professionals for his comeback biotech fund (Endpoints)
• Cellectis signs $760M milestone deal with NK upstart; Immunocore brings on AstraZeneca vet to shepherd bispecific launch plans (Endpoints)
• Sesen Bio, after years on the edge of irrelevancy, scores speedy review for long gestating bladder cancer program (Endpoints)
• GSK starts Phase III RSV candidate vaccine programme for older adults (Press)

• BD drug-coated balloon faces uphill battle in FDA panel review (MedtechDive)
• BD secures EUA, CE Mark for molecular test for both COVID-19 and flu (MassDevice)
• Axonics implantable neurostimulator wins FDA PMA supplemental approval (MassDevice)

• Pharmaceutical Patents on Manufacturing Methods: Groundless or Well-Supported? (Harvard Bill of Health)